Ozempic and menopause: what the studies really show

What these medications really are

GLP-1 is a hormone your gut produces when you eat. It alerts the pancreas, slows the emptying of the stomach and informs the brain that a meal is under way. The medications everyone is talking about (semaglutide, tirzepatide, marketed under various names) are modified copies of this hormone, designed to last several days instead of a few minutes.

This detail changes everything in how to understand them. They burn nothing, they speed up no metabolism. They make satiety come earlier and last longer, and they dampen what research calls food noise, that permanent mental preoccupation with food that many women describe without ever having had a word to name it.

They were first developed for type 2 diabetes. The effect on weight, observed along the way, led to distinct dosages and indications. The two uses coexist today, under brand names and with distinct prescribing conditions.

The French framework: who can take them

This is the part that is talked about least, and yet it is the one that decides everything. In France, GLP-1 analogs authorized in the treatment of obesity are, according to the ANSM, second-line treatments, in case of failure of nutritional management, and they are used in combination with a low-calorie diet and physical activity. The agency states in black and white that they must not be used for cosmetic weight loss in people without excess weight or a weight-related health problem, and recalls that such use exposes people to side effects that are sometimes serious.

Since June 2025, the ANSM has allowed any doctor to initiate and renew these treatments, whereas the initial prescription was previously reserved for specialists. In parallel the agency maintains enhanced surveillance : it is monitoring in particular a signal of anterior ischemic optic neuropathy, as well as notifications of pregnancies occurring in women on oral contraception and on semaglutide.

The HAS, for its part, considered in October 2024 that the clinical benefit of semaglutide in obesity was substantial only in adults with an initial BMI of at least 35 kg/m², after the failure of properly conducted nutritional management. It also stresses that efficacy and safety data beyond two years remain limited, which calls for regular reassessment. Its care pathway guide on overweight and obesity in adults points the same way : the medication comes into play only after the failure of lifestyle changes, and management "does not come down to reaching a weight target".

A final word about Ozempic, whose name circulates the most. The ANSM recalls that it must be prescribed only in insufficiently controlled type 2 diabetes. Diverting it for weight loss exposes people to potentially serious side effects, digestive disorders, pancreatitis, hypoglycemia, and reduces the availability of the medication for people with diabetes who need it.

Why menopause changes the picture

One thing has to be said up front : the body in its fifties does not gain weight only because it eats too much. The fall in estrogen changes where fat is deposited. It leaves the hips and thighs for the abdomen, including around the organs, that visceral fat which weighs on cardiovascular risk and metabolic risk far more than the number on the scale.

In parallel, muscle mass declines. A review devoted to the management of obesity at menopause describes precisely this double mechanism : fat redistribution and loss of lean mass⁵. That is what explains a very common and very disconcerting experience : weight barely moves, and yet clothes no longer fit the same way.

This nuance matters for what follows, because it shifts the right question. It is not "how many kilos am I going to lose?", it is "what exactly am I losing : fat, or muscle?"

What the studies report in menopausal women

The literature specific to women and specific to menopause is still thin : that is an honest limitation to state before any figure. Most large trials included women, without analyzing separately those who were in perimenopause or beyond.

A few pieces of work fill this gap. One study assessed the effectiveness of low doses of semaglutide on weight loss and body composition in women in their menopause¹. The fact that it measures body composition, and not only weight, is exactly what should be looked at at this age.

Two recent reviews take stock of GLP-1 analogs in perimenopausal and postmenopausal women³⁴. They describe a field in motion, where the data specific to this population are still being built.

What can be said without exaggeration : these medications also work after menopause, and nobody claims today to have ten years of hindsight on this precise population.

Hormone therapy and GLP-1: the question arises

If you are taking menopause hormone therapy, the question of its interaction with a GLP-1 analog is legitimate, and it has been raised by research. An analysis compared the weight response to semaglutide in postmenopausal women according to whether or not they were taking hormone therapy².

This is the kind of result to handle with care : an association observed in a group of patients is not proof that one treatment makes the other work better. But it is reason enough for your doctor to have both pieces of information in hand : MHT and a weight treatment plan are not discussed in two separate consultations.

The point to watch: muscle

Any rapid weight loss is accompanied by a loss of lean mass. This is not specific to these medications : it is true of a restrictive diet, of bariatric surgery, of illness. What is specific to your fifties is that muscle capital is already declining.

In practice, that means the question of support is not an optional extra. A sufficient protein intake and regular strength training are the two levers that make the difference between losing fat and weakening yourself. We discuss this in our article on exercise after 50.

The most frequent side effects are digestive : nausea, slowed transit, reflux. They often ease with time and depend a great deal on how fast the dose is increased. There are also contraindications and situations that require particular monitoring : that is the conversation to have with your doctor, not with a forum.

If you are still in perimenopause

An often forgotten point : in perimenopause, pregnancy remains possible. Now, these medications slow gastric emptying, which has raised a concern about the absorption of contraceptive pills.

This question has been tested for semaglutide, and the study concludes that it does not reduce the bioavailability of a combined ethinylestradiol/levonorgestrel pill⁶. Be careful about the scope of this result : it concerns one molecule and one specific combination, not every possible combination. If this concerns you, ask the question explicitly : it is also the subject of our article on contraception in perimenopause.

And this result does not close the matter. The ANSM reports having received, internationally, notifications of pregnancies occurring in women who were taking oral contraception and semaglutide. The question is among the safety signals under evaluation by the ANSM and the European Medicines Agency. If your contraception matters, this point therefore deserves to be raised explicitly in consultation rather than inferred from a single trial.

What these medications do not settle

They act neither on hot flashes, nor on sleep, nor on dryness, nor on mood. They are treatments for weight and metabolism, not treatments for menopause.

Nor do they settle the reason why we eat. Emotional hunger, eating that soothes stress or boredom, broken nights that disturb the next day's appetite : none of that disappears with a weekly injection. Our article on cortisol and weight gain covers that side of things.

Finally, stopping raises a real question. Weight frequently goes back up when the treatment stops, which leads people to think of it as a long-term treatment and not as a course. It is a decision that commits you, financially and medically.

In short

These medications are neither the miracle nor the scandal they are described as in turn. They are treatments that are effective on weight, whose data specific to menopausal women are being built at this very moment, and which require support (protein, muscle, monitoring) so that what is lost really is fat.

If the question crosses your mind, the right first step is not a prescription : it is an honest assessment of what your body has been doing for the past few years, and a medical conversation where MHT, weight and cardiovascular risk are looked at together.

⚠️ This article is provided for informational and educational purposes only. It does not replace medical advice, diagnosis or treatment. Always consult your doctor or a qualified health professional with any questions about your health.

How we work: our editorial method · Written and verified by Bouchra, editorial lead.